| [1] |
Study Group of Inflammatory Bowel Disease, Chinese Society of Gastroenterology, Chinese Medical Association. Chinese consensus on diagnosis and treatment in inflammatory bowel disease(2018, Beijing)[J]. Chin J Pract Intern Med, 2018, 38(9): 796-813. DOI: 10.19538/j.nk2018090106. |
| [2] |
|
| [3] |
SHAN CY, ZHANG QQ, XIAO Y, et al. Incidence and risk factor of extraintestinal manifestations in children with inflammatory bowel disease[J]. Chin J Pediatr, 2019, 57(9): 694-699. DOI: 10.3760/cma.j.issn.0578-1310.2019.09.009. |
| [4] |
BOONSTRA K, van ERPECUM KJ, VAN NIEUWKERK KM, et al. Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease[J]. Inflamm Bowel Dis, 2012, 18(12): 2270-2276. DOI: 10.1002/ibd.22938. |
| [5] |
BJÖRNSSON E, OLSSON R, BERGQUIST A, et al. The natural history of small-duct primary sclerosing cholangitis[J]. Gastroenterology, 2008, 134(4): 975-980. DOI: 10.1053/j.gastro.2008.01.042. |
| [6] |
CHARATCHAROENWITTHAYA P, ANGULO P, ENDERS FB, et al. Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis[J]. Hepatology, 2008, 47(1): 133-142. DOI: 10.1002/hep.21960. |
| [7] |
LEES CW, BARRETT JC, PARKES M, et al. New IBD genetics: common pathways with other diseases[J]. Gut, 2011, 60(12): 1739-1753. DOI: 10.1136/gut.2009.199679. |
| [8] |
YANG H, QIAN JM. Current status of research on inflammatory bowel disease with special comorbidities[J]. J Clin Hepatol, 2020, 36(7): 1441-1443. DOI: 10.3969/j.issn.1001-5256.2020.07.001. |
| [9] |
WANG JB. Association between inflammatory bowel disease and chronic liver diseases and related management strategies[J]. J Clin Hepatol, 2020, 36(7): 1444-1449. DOI: 10.3969/j.issn.1001-5256.2020.07.002. |
DownLoad:
